We report a novel strategy, called end-product (EP) amplification, capable of enhancing the sensitivity of immunohistochemical procedures by about an order of magnitude or more. The strategy employs an antibody (anti-EP) to the product generated by the action of horseradish peroxidase on 3,y-diaminobenzidine (DAB), and can be extended to the products of other enzymes as well, e.g., alkaline phosphatase. Amplification is the consequence of the ability of anti-EP to detect the multiplicity of product moelcula resulting from the tumover of substrate by a single enzyme molecule. The subsequent detection of anti-EP was by biotinylated goat anti-rabbit antibody, followed by avidin-peroxidase and DAB or by avidin-alkaline phosphatase and Vector Red. Further amplification can be accomplished by repeated cydes of the protocol. Anti-EP was produced by immunization with a bovine serum albumin (BSA) conjugate of a soluble polymer of DAB, prepared by a carefully controlled reaction of DAB with horseradish peroxidase and hydrogen peroxide. Coupling to BSA (and to RSA) was accomplished with glutaraldehyde. The titer of anti-EP was established by ELISA.
Introduction
Enzyme-labeled antibodies are in common use in clinical and research laboratories for immunoassays and for identification of cell or tissue components. With respect to the latter, identification is usually performed by Western blotting after solubilization and electrophoresis, or by immunohistochemical procedures. In both cases, the signal for the presence of the target antigen is a deposit of a pigmented product of an enzyme-substrate reaction at the site of the antigen. The most common enzymes in use are alkaline phosphatase and horseradish peroxidase. Columbia Univ., 701 West 168 St., New York. NY 10032. sia were immunolabeled for the following lymphoid markers: CD3, CD20, CD30, CD45RA, and CD 68. EP amplification with anti-EP was also applied to cases of CMV pneumonia and cerebral toxoplasmosis to determine whether this procedure could improve detection of the infectious agents. Immunolabeling of the primary antibody was performed by the avidin-biotin-peroxidase technique with DAB as the reaction substrate. The specificity of EP amplification was tested by demonstrating binding of anti-EP with Vector Red with the generation of a fluorescence end-point. There was complete congruence in the distribution of the DAB signal and the red immunofluorescence representing EP amplification. The intensity of the DAB signal was increased as much as 16-fold by EP amplification, making possible a reduction in the amount of the primary antibody by as much as 85-9Oo/o. Sensitivity also increased with respect to weakly expressed antigens and low concentrations of infectious agents. ( J Hisrochem Cyrochem 44319-824, 19%) KEY WORDS: Peroxidase; 3,3'-Diaminobenzidine; Signal amplification; Immunocytochemistry; Immunofluorescence; Lymphocyte markers.
There are circumstances that require the signal to be amplified. These include the presence of low levels of the target antigen and/or limited availability or high cost of the target-specific antibody. Some representative amplification procedures are described in a review (Avrameas, 1992) . Amplification of the signal produced by peroxidase is usually accomplished through the use of peroxidase-labeled anti-peroxidase antibody (PAP), biotin-avidin-peroxidase techniques, or the linking of primary antibodies to multiple enzyme molecules via polyvalent polymers (e.g., EPOS reagents; Dako, Carpinteria, CA), procedures that can produce significant amplification (Sternberger, 1986; Landsdorp et al., 1984; Sternberger, 1970) . Other strategies have been reported to produce enhanced amplification, some of which have been applied to immunohistochemical systems. Among them are methods that exploit enzyme and cofactor cascades (Zaidi et al., 1990; Kemeny et al., 1989; Johansson et al., 1985; Blake et al., 1984) . In another strategy, called catalyzed reporter deposition (CARD), substrates are designed to de-820 CHEN, SZABOLCS, MATSUSHIMA, ERLANGER posit a tagged product capable of producing an amplifiable signal, e.g., a biotinylated product that can be labeled with multiple avidin-enzyme conjugates (Bobrow et al., 1989 (Bobrow et al., ,1991 (Bobrow et al., ,1992 .
We report a novel strategy, applicable to immunohistochemistry, which, in principle, is capable of exponential amplification of a peroxidase signal. It makes use of an antibody to the end-product of the action of peroxidase on 3,3'-diaminobenzidine (DAB). Because a single enzyme molecule converts many substrate molecules into product, a procedure that recognizes molecules of product rather than molecules of enzyme should produce amplification of considerable magnitude. We have found this to be the case.
Materials and Methods
Preparation of Antigen and Specific Anti-End-product (Anti-EP) Antibody. Bovine serum albumin (BSA) (48 mg; 0.72 pmoles) was dissolved in 2 ml of PBS and the pH adjusted to 6.5 with dilute NaHCO3.
DAB.4HCI (7.6 mg; 21 pmoles) was dissolved in 5 ml of PBS. Two pl of 30% hydrogen peroxide was added. To this solution was added 50 pI of a solution of 0.5 mg of horseradish peroxidase in 300 pI of distilled water. Color began to appear immediately. When the solution became bright red, a spatular tip of palladium on carbon (10%) (Easunan; Rochester, NY) was added immediately, with mixing, to stop the reaction. The suspension was centrifuged and the supernatant added to the BSA solution. The pH was again adjusted to 6.5 and 40 pl of 25% glutaraldehyde was added to the solution, which was allowed to stand at room temperature (RT) for 8 hr. Then 40 PI of ethanolamine was added to destroy the remaining glutaraldehyde and the solution was dialyzed overnight against PBS in a cold room. The conjugate was red-brown in color.
A rabbit serum albumin (RSA) conjugate was prepared in an identical way.
Rabbits were immunized with the BSA conjugate in complete Freund's adjuvant and boosted several times with the antigen in incomplete Freund's adjuvant.
The presence of specific antibody was monitored by Ouchterloney and by ELISA using the RSA conjugate as the antigen, as follows.
Polystyrene 96-well microplates (Corning 25855) were coated with 100 p1 of the RSA conjugate ( overnight at 4°C. The plates were washed three times with PBS containing 0.1% Tween 20 (PBS-T) and 100 p1 of various dilutions of the antisera in PBS-T containing 1% horse serum were incubated in the wells at 37°C for 2 hr. This was followed by three washes with PBS-T. Then a 1:1000 dilution of peroxidase-labeled goat anti-rabbit IgG (Sigma; St Louis, MO) was added to each well. After a 1-hr incubation at 37°C and three washes with PBS-T, development was carried out with 100 pl of substrate (7 mg of o-phenylenediamine dihydrochloride in 10 ml of 0. (a,b) , a hyperplastic tonsil (c-f), and a case of CMV pneumonia (g,h) with antisera to CD30 (1:800) (a,b) , CD20
( 1:3200) (c,d) , CD68 ( W O ) (e,f), and CMV (1:200) (g,h) . The signal in EP-amplified sections (a,c,e,g) is much stronger than in the unamplified control sections stahed with the conventional avidin-biotin technique (b,d,f,h) , when equal dilutions of the primary Ab were used. The numbers of CD 30-immunoreactive Reed -Sternberg cells (a,b) , CDPO-positive B-lymphocytes (c,d) , both in the mantle zone (M) and the follicular center (F) of tonsil lymph follicles, CWreactive macrophages (e,f), and CMV-infected alveolocytes are also increased in EP-amplified (a,c,e,g) vs unamplified (b,d,f,h) Immunostaining was performed on formalin-foced, paraffin-embedded tissues obtained from the Surgical Pathology files of the College of Physicians and Surgeons, Columbia University. Markers for B-(anti-CDZO and anti-CD45RA) and T-(anti-CD3 and anti-CD 45RO) lymphocytes and macrophages (anti-CD68) were applied to tonsil tissue, in which the distribution of T-(interfollicular zones) and B-cells (germinal centers and mantle zones) is known. Also examined were five cases of Hodgkin's disease, in which an additional marker (anti-CD30) that labels Hodgkin's cells and Reed-Sternberg cells was used. Immunolabeling for infectious agents was performed on cases of cerebral toxoplasmosis, progressive multifocal leukoencephalopathy (JC virus), and cytomegalovirus (CMV) pneumonia. The dilutions of primary antibodies for optimal staining, defined as maximal sensitivity of detection with and without the anti-EP amplification system in the absence of background staining, are listed in Table 1 . Optimal staining without amplification, as determined by serial dilution experiments, was in agreement with the manufacturer's recommendations.
The tissue sections were first treated with 1.5% hydrogen peroxide to quench endogenous peroxidase activity. For CD30 detection, antigen retrieval was accomplished by boiling for 20 min in 1.2 liters of 0.01 M citrate buffer, pH 6.0, in a microwave oven; 15-min pepsin digestion (0.01 gldl at pH 1.5) was used for CMV and CD68. Nonspecific staining was minimized by 20-min blocking with 10% horse serum in PBS for the monoclonal antibodies or 10% goat serum in PBS for the polyclonal antisera.
Sections were incubated with serial twofold dilutions of primary antibody for 1 hr at RT, followed by biotinylated second antibody; development was with a biotin-streptavidin-peroxidase kit (Vector Laboratories; Burlingame, CA) (Hsu et al., 1981) . Peroxidase activity was visualized with DAB (250 pglml in PBS, from a stock solution of 1.25 gl50 ml of diethylene glycol) for 3-5 min. The sections were then rinsed thoroughly with tapwater for 30 min to remove unpolymerized DAB (Sigma) and blocked again with 10% goat serum in PBS for 20 min.
Amplification with anti-EP was accomplished by incubating one set of slides with a 1:500 dilution of the anti-EP in PBS containing 3% goat serum for 30 min at RT, followed by biotinylated goat anti-rabbit IgG. To control for possible signal enhancement by the secondary anti-rabbit IgG, unamplified controls were run in which anti-EP was omitted. Apart from the omission of anti-EP, unamplified controls were treated exactly the same as ERamplified sections. Development was with the Vector Laboratories biotin-avidin-peroxidase kit, which includes a biotinylated goat anti-rabbit antibody. DAB was applied for 1-2 min to demonstrate anti-EP binding and the degree of anti-EP amplification. The latter was determined by calculating the ratios of primary antibody dilutions showing equal sensitivity of detection in anti-EP amplified sections and unamplified controls. In another set of experiments, designed to give an anti-EP amplified fluorescent signal, slides with and without application of anti-EP were developed with a biotin-streptavidin-alkaline phosphatase kit, which was visualized with Vector Red (Vector Laboratories).
Appropriate negative controls, in which nonspecific mouse and rabbit antibodies were substituted for specific primary antibodies, gave negligible background
Results
The signal amplification strategy reported in this article makes use of an antibody (anti-EP) raised in rabbits to a BSA conjugate of a polymeric intermediate formed by a controlled reaction of horseradish peroxidase and Hz02 on the substrate DAB. Amplification is the result of the ability of anti-EP to detect the multiplicity of product molecules formed by the action of a single molecule of enzyme on DAB. Figure 1 is the titer of anti-EP as determined by an ELISA in which a 96-well plate was coated with a rabbit serum albumin (RSA) conjugate of the polymeric DAB product. Reproducible titers could be obtained at dilutions of antisera as high as 1:15,000, with a development time of only 10 min.
Shown in
In immunohistochemical studies, the intensity of immunolabeling was increased 8-to 16-fold over conventional detection systems by using anti-EP amplification (Table 1 ). Figure 2 illustrates the striking difference in signal intensity and number of immunoreactive cells between EP-amplified sections (Figures 2a, 2c, 2e , and 2g) and unamplified controls (Figures 2b, 2d, 2f, and 2h) , when equal dilutions of the primary Ab were applied. The profile of immunoreactivity with respect to cell type remained unchanged before and after EP amplification for each Ab tested.
AntLCD30 immunoreactivity was still confined t o Reed-Sternberg cells in cases of Hodgkin's disease (Figures 2a and 2b) . Anti-CD20 (Figures 2c and 2d ) and anti-CD68 (Figures 2e and 2f ) specifically labeled B-lymphocytes and macrophages, respectively, in germinal centers of hyperplastic tonsils. Immunoreactivity for CMV occurred only in cells displaying the characteristic pathomorphologic changes of CMV infection (Figures 2g and 2h ). Nonspecific labeling of cells lacking the respective epitopes (CD20, CD30, CD68, or CMV) did not occur.
The specificity of anti-EP amplification was also tested by using a fluorescence end-point (Vector Red) for detection of anti-EP immunoreactivity. Slides stained with antibodies to CD30 (Figures  3a-3d ) and to toxoplasma (Figures 3e-3h ) showed complete congruence between the DAB signal, representing the distribution of the primary antibodies, and the red fluorescence that represents anti-EP binding (Figures 3a, 3b, 3e, and 3f) , demonstrating high specificity of the anti-EP labeling process. The fluorescence signal was absent (Figures 3c and 3g) , despite a strong DAB signal ( Figures  3d and 3h) , when anti-EP A b was omitted. This is further evidence that, in the unamplified controls, binding of biotinylated secondary goat anti-rabbit antibody to the primary antibodies did not occur.
Discussion
We have demonstrated a procedure capable of an 8to 16-fold amplification of a signal produced by the action on a substrate of an enzyme-linked antibody (Table 1 ). Further optimization should be possible, as is the possibility of gaining increased amplification by repeating the cycle. We have shown that this process of amplification produces minimal background and allows the recognition of antigenic markers present at low concentrations, making possible a significant reduction (85-90Y0) in the amount of primary antibody necessary to produce a positive signal, a major cost-saving advantage in laboratories that routinely perform immunohistochemical procedures. The enzyme we chose to work with was horseradish peroxidase and the substrate DAB but, in principle, the methodology should be applicable to other enzyme-substrate systems and, moreover, it is not limited to signals produced by immune recognition.
The anti-EP used in the experiments described here is an antiserum containing polyclonal antibodies. Similar results can be obtained with globulin fractions, specifically purified antibodies,
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. r- -I and with biotinylated anti-EP followed by avidin-peroxidase. In preliminary experiments, amplifications as high as 50-fold were obtained with specifically purified rabbit anti-EP. Monoclonal anti-EP antibodies have also been raised, which have the advantage of uniformity from batch to batch and availability in essentially unlimited quantities.
The strategy of end-product amplification has also been applied to alkaline phosphatase action on tetrazolium substrates, which will be described in a subsequent report (manuscript in preparation), as will the application of end-product amplification to membrane immunoassays.
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